1. FDA requires NAION warning across all GLP-1 receptor agonists
On 9 November FDA announced that application holders for all GLP-1 receptor agonists, including semaglutide, liraglutide, dulaglutide, tirzepatide and orforglipron, must add the potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of labelling. FDA's meta-analysis of 126 randomised trials found 6.4 NAION events per 100,000 person-years with GLP-1 RAs versus 3.8 with comparators; a Sentinel cohort study showed an increased risk versus DPP-4 inhibitors (HR 1.43) but no significant difference versus SGLT-2 inhibitors. Prescribers are told to refer suspected cases promptly to an ophthalmologist and to consider stopping treatment in patients who develop NAION unless benefits clearly outweigh the risk. For safety teams, this is a class-wide label change built on pooled trial data and real-world evidence rather than spontaneous reports alone, and it will prompt updates to reference safety information and to how ocular events are coded and followed up. FDA Drug Safety Communication, 9 Nov 2026
2. EMA consults on revised guidance for reproduction and breastfeeding risk in product information
EMA has published Revision 1 of its draft guideline on risk assessment of medicinal products in human reproduction and breastfeeding, "from data to product information" (EMA/CHMP/PRAC/203927/2005 Rev.1), which will replace the 2008 guideline. The draft covers how nonclinical reproductive toxicity data and human clinical data are assessed and translated into SmPC wording on pregnancy, fertility and lactation. Public consultation runs from 9 November 2026 to 28 February 2027. Labelling, nonclinical and PV teams should review the draft, as it will shape how pregnancy and breastfeeding information, including data from pregnancy registries and exposure reports, is reflected in product information. EMA scientific guideline page, 9 Nov 2026
3. Health Canada: diphenhydramine capsules recalled over nitrosamine impurity
On 9 November Health Canada published a Type II recall of seven lots of Pendopharm PDP-Diphenhydramine 25 mg and 50 mg capsules because the nitrosamine impurity N-nitroso-N-desmethyl diphenhydramine may be out of specification. Distribution was national and the recall is at retail level; people are advised to consult a healthcare provider before stopping use. The case shows that nitrosamine drug substance-related impurities continue to surface in long-established products, and that quality-driven recalls need clear coordination between quality, regulatory and PV functions. Health Canada recall notice, 9 Nov 2026
4. Syntara pauses recruitment in topical scar trial after skin irritation
Syntara announced on 10 November that it has paused recruitment in its Phase 1b study of SNT-9465, a topical pan-lysyl oxidase inhibitor, in hypertrophic sternotomy scars, after reports of mild to moderate skin irritation in some participants identified in an internal review of blinded local tolerability data. The company will review unblinded data from completed and ongoing participants this quarter and then decide whether to restart recruitment or end the study. Although the events are not serious, the pause illustrates how blinded aggregate review of local tolerability can trigger a recruitment hold in early development. Syntara ASX announcement, 10 Nov 2026
This news brief is for information only and is not medical or regulatory advice. Source links open the original publication in a new tab.
Follow Safety Strategy on LinkedIn (opens in a new tab) for updates. All news briefs · News and articles